Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07014618

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States

Location status: Recruiting

Location contact

Shearwood McClelland III, MD

CONTACT

[email protected]

405-271-3016

About this study

The study aims to utilize qualitative measurements, including pre- and post-treatment breast and prostate cancer surveys tailored to specific ethnic groups-Native American, African American, and Hispanic/Latino populations. In addition to these culturally relevant surveys, participants will also complete the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) score to evaluate the financial and functional impact of their cancer care experience.

Those who choose to complete the surveys will be offered navigation assistance as part of the study intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
  • Subjects must be 18 years of age or older. This study requires informed consent by the subject.
  • Subjects must be of African American race, Native American race, or Hispanic ethnicity.
  • Subjects scheduled to undergo RT for Cancer Treatment.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • Subjects NOT of African American race, Native American race or Hispanic ethnicity.
  • Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer.
  • Subjects younger than 18 years old.

Treatment and study plan

Pre & Post Surveys

Other

As part of this intervention, patients will complete a pre-treatment questionnaire at the time of consent, which can be administered in person, over the phone, or through the mHealth mobile app, based on their preference. One month after treatment, patients will complete a post-treatment questionnaire using their chosen method. At the six-month mark, patients will complete an additional post-treatment questionnaire along with the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) survey.

Opt Out of Questionnaire

Other

As part of this intervention, patients declined to participate in the optional questionnaire. However, their data will still be collected through chart review and will be compared to the data of patients who accepted both the questionnaire and navigation services.

Primary outcomes

  1. Number of Patients Who Complete Radiation Therapy

    Time frame: 6 months

    Survey-based methods will be used to assess barriers facing under-represented minority cancer patient access to patient navigation. This study will use a patient-completed, culturally sensitive survey adapted from "Walking Forward," a patient navigator program providing culturally appropriate community education on cancer, screening and treatment, to include barriers to specific RT regimens, and concerns regarding transportation.

Secondary outcomes

  1. Number of Patients Successfully Impacted by Patient Navigation on Radiation Therapy

    Time frame: 6 Months

    Assess the impact of patient navigation on patient access to radiation oncology care [Time Frame: Immediately following radiotherapy treatment]

    Qualitative mechanisms will be used to assess the impact of patient navigation on patient access to radiation oncology care and consequently utilization of standard of care modalities. This study will use patient-completed surveys to evaluate the impact of patient navigation on access to short-course RT by using a culturally sensitive survey adapted from "Walking Forward", a patient navigator program providing culturally appropriate community education on cancer, screening and treatmen. The feedback provided by patients on the impact of patient navigation will be compared- before and after RT, and will also be compared against feedback from patients who did not received patient navigation.

  2. Investigate The Differences in Financial Toxicity Levels

    Time frame: 6 Months

    This study will use patient-completed surveys to evaluate the impact of financial hardship in African-American breast cancer patients. Patient scores from an evidence-based tool, "The COmprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT)" will be used to compare financial hardship in each group of patients with early-stage breast cancer who have received a lumpectomy. Surveys will investigate differences in financial toxicity survery scores experienced by underrepresented minorities receiving conventional versus short-course RT.

Study contacts

Contact information is provided by the study sponsor or research team.

Lead Onco Nurse

CONTACT

[email protected]

405-271-8777

Shearwood McClelland III, MD

CONTACT

[email protected]

405-271-3016

Sponsors and collaborators

Lead sponsor

University of Oklahoma

Other

Collaborators

  • Gilead Sciences
  • Radiation Therapy Oncology Group
  • Susan G. Komen Breast Cancer Foundation

Registry information

Official study title

Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Jun 11, 2025
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.